Adverum Biotechnologies Inc (ADVM.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2017||Chairman of the Board|
|55||2018||Interim President and Chief Executive Officer, Chief Financial Officer|
|50||2016||Chief Science and Technology Officer|
|44||2017||Vice President, General Counsel|
|2018||Interim Chief Medical Officer|
- BRIEF-Adverum Biotechnologies Reports Q1 Loss Per Share $0.30
- BRIEF-Adverum Biotechnologies Announces Leadership Changes
- BRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMD
- BRIEF-Adverum Biotechnologies Q4 Loss Per Share $0.32
- BRIEF-Adverum Biotechnologies Announces Completion Of Dosing Of First Cohort